Phaseline

Companies › Tarian Pharma

Tarian Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TAR-0520 Gel
Brimonidine tartrate - selective alpha-2 adrenergic receptor agonist
ADRA2A, ADRA2B, ADRA2CPhase 2EGFR Inhibitor-associated Rash–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06818058TAR-0520 GelPhase 2EGFR Inhibitor-associated RashImmunologySep 2026

Targets

ADRA2A (1) ADRA2B (1) ADRA2C (1)

Companies with the same targets

Guangzhou Novaken Pharm BioXcel Therapeutics Teikoku Pharma USA Alcon Research Acer Therapeutics Santen SAS Pharmazz ARS Pharmaceuticals Terran Biosciences Australia Tecnoquimicas

Companies built like this

Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.